Annual Securities Report — FY2025
What DAIKEN MEDICAL CO.,LTD. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-17View the original on EDINET
How much it says
57Typical
What moved here
12named for the first time
Its own wording
51terms
Which filing this is
36/ 36newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the fiscal year, sales increased, but operating income, ordinary income and net income all declined due to higher material costs and increases in personnel and research and development expenses. The Company also incurred ¥236 million in capital expenditure and disclosed sustainability and climate-related risks and opportunities.
Komori's summary of this document, not the document's own words.57Typical
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
68
Detailed
60
Detailed
62
Detailed
50
Typical
15
Almost nothing
68
Detailed
31
Thin
31
Thin
69
Detailed
79
Very detailed
73
Detailed
R&D spend4億円Money spent making new things.
Cash left over2億円Cash from the business, less what went into equipment.
Spent on equipment2億円Plants, machines — things meant to last.
Employees185Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.